Merck ($MRK) may have to rethink its math on the Cubist ($CBST) buyout. Announcing the $9.5 billion transaction Monday, the company pointed to an earnings bump beginning in 2016. But later in the day, a U.S. court nixed all but one of the patents covering its top seller, Cubicin--and that patent expires in 2016. With [...]